76 related articles for article (PubMed ID: 26687750)
1. Enhanced Ehrlich tumor inhibition using DOX-NP and gold nanoparticles loaded liposomes.
Mady MM; Al-Shaikh FH; Al-Farhan FF; Aly AA; Al-Mohanna MA; Ghannam MM
Pak J Pharm Sci; 2015 Nov; 28(6 Suppl):2321-5. PubMed ID: 26687750
[TBL] [Abstract][Full Text] [Related]
2. Ehrlich tumor inhibition using doxorubicin containing liposomes.
Elbialy NS; Mady MM
Saudi Pharm J; 2015 Apr; 23(2):182-7. PubMed ID: 25972739
[TBL] [Abstract][Full Text] [Related]
3. Comparison of free and liposome encapsulated doxorubicin tumor drug uptake and antitumor efficacy in the SC115 murine mammary tumor.
Mayer LD; Bally MB; Cullis PR; Wilson SL; Emerman JT
Cancer Lett; 1990 Sep; 53(2-3):183-90. PubMed ID: 2208078
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and characterisation of liposomal doxorubicin with loaded gold nanoparticles.
Karimi Zarchi AA; Amini SM; Salimi A; Kharazi S
IET Nanobiotechnol; 2018 Sep; 12(6):846-849. PubMed ID: 30104461
[TBL] [Abstract][Full Text] [Related]
5. Improved antitumor activity and reduced toxicity of doxorubicin encapsulated in poly(ε-caprolactone) nanoparticles in lung and breast cancer treatment: An in vitro and in vivo study.
Cabeza L; Ortiz R; Prados J; Delgado ÁV; Martín-Villena MJ; Clares B; Perazzoli G; Entrena JM; Melguizo C; Arias JL
Eur J Pharm Sci; 2017 May; 102():24-34. PubMed ID: 28219748
[TBL] [Abstract][Full Text] [Related]
6. Doxorubicin loaded gold nanoparticles: Implication of passive targeting on anticancer efficacy.
Dhamecha D; Jalalpure S; Jadhav K; Jagwani S; Chavan R
Pharmacol Res; 2016 Nov; 113(Pt A):547-556. PubMed ID: 27693276
[TBL] [Abstract][Full Text] [Related]
7. Doxorubicin-loaded amphiphilic polypeptide-based nanoparticles as an efficient drug delivery system for cancer therapy.
Lv S; Li M; Tang Z; Song W; Sun H; Liu H; Chen X
Acta Biomater; 2013 Dec; 9(12):9330-42. PubMed ID: 23958784
[TBL] [Abstract][Full Text] [Related]
8. A comparative study of folate receptor-targeted doxorubicin delivery systems: dosing regimens and therapeutic index.
Scomparin A; Salmaso S; Eldar-Boock A; Ben-Shushan D; Ferber S; Tiram G; Shmeeda H; Landa-Rouben N; Leor J; Caliceti P; Gabizon A; Satchi-Fainaro R
J Control Release; 2015 Jun; 208():106-20. PubMed ID: 25869964
[TBL] [Abstract][Full Text] [Related]
9. Doxorubicin-loaded nanocarriers: A comparative study of liposome and nanostructured lipid carrier as alternatives for cancer therapy.
Fernandes RS; Silva JO; Monteiro LOF; Leite EA; Cassali GD; Rubello D; Cardoso VN; Ferreira LAM; Oliveira MC; de Barros ALB
Biomed Pharmacother; 2016 Dec; 84():252-257. PubMed ID: 27664949
[TBL] [Abstract][Full Text] [Related]
10. Enhanced intracellular uptake of sterically stabilized liposomal Doxorubicin in vitro resulting in improved antitumor activity in vivo.
Xiong XB; Huang Y; Lu WL; Zhang H; Zhang X; Zhang Q
Pharm Res; 2005 Jun; 22(6):933-9. PubMed ID: 15948037
[TBL] [Abstract][Full Text] [Related]
11. Enhanced Cytotoxicity of Folic Acid-Targeted Liposomes Co-Loaded with C6 Ceramide and Doxorubicin: In Vitro Evaluation on HeLa, A2780-ADR, and H69-AR Cells.
Sriraman SK; Pan J; Sarisozen C; Luther E; Torchilin V
Mol Pharm; 2016 Feb; 13(2):428-37. PubMed ID: 26702994
[TBL] [Abstract][Full Text] [Related]
12. Vascular targeting of doxorubicin using cationic liposomes.
Wu J; Lee A; Lu Y; Lee RJ
Int J Pharm; 2007 Jun; 337(1-2):329-35. PubMed ID: 17275230
[TBL] [Abstract][Full Text] [Related]
13. Comparison of pharmacokinetics, tissue distribution and pharmacodynamics of liposomal and free doxorubicin in tumour-bearing mice following intratumoral injection.
Ren S; Li C; Dai Y; Li N; Wang X; Tian F; Zhou S; Qiu Z; Lu Y; Zhao D; Chen X; Chen D
J Pharm Pharmacol; 2014 Sep; 66(9):1231-9. PubMed ID: 24716458
[TBL] [Abstract][Full Text] [Related]
14. Binding and internalization of NGR-peptide-targeted liposomal doxorubicin (TVT-DOX) in CD13-expressing cells and its antitumor effects.
Garde SV; Forté AJ; Ge M; Lepekhin EA; Panchal CJ; Rabbani SA; Wu JJ
Anticancer Drugs; 2007 Nov; 18(10):1189-200. PubMed ID: 17893520
[TBL] [Abstract][Full Text] [Related]
15. Improved antitumor activity and reduced myocardial toxicity of doxorubicin encapsulated in MPEG-PCL nanoparticles.
Sun C; Zhou L; Gou M; Shi S; Li T; Lang J
Oncol Rep; 2016 Jun; 35(6):3600-6. PubMed ID: 27109195
[TBL] [Abstract][Full Text] [Related]
16. Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model.
Moosavian SA; Abnous K; Badiee A; Jaafari MR
Colloids Surf B Biointerfaces; 2016 Mar; 139():228-36. PubMed ID: 26722819
[TBL] [Abstract][Full Text] [Related]
17. Efficient tumor regression by a single and low dose treatment with a novel and enhanced formulation of thermosensitive liposomal doxorubicin.
Tagami T; Ernsting MJ; Li SD
J Control Release; 2011 Jun; 152(2):303-9. PubMed ID: 21338635
[TBL] [Abstract][Full Text] [Related]
18. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
Park JW; Hong K; Kirpotin DB; Colbern G; Shalaby R; Baselga J; Shao Y; Nielsen UB; Marks JD; Moore D; Papahadjopoulos D; Benz CC
Clin Cancer Res; 2002 Apr; 8(4):1172-81. PubMed ID: 11948130
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release.
Kong G; Anyarambhatla G; Petros WP; Braun RD; Colvin OM; Needham D; Dewhirst MW
Cancer Res; 2000 Dec; 60(24):6950-7. PubMed ID: 11156395
[TBL] [Abstract][Full Text] [Related]
20. Enhanced antitumor and anti-metastasis efficiency via combined treatment with CXCR4 antagonist and liposomal doxorubicin.
Mei L; Liu Y; Zhang Q; Gao H; Zhang Z; He Q
J Control Release; 2014 Dec; 196():324-31. PubMed ID: 25450404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
